Fondazione IRCCS San Gerardo dei Tintori

Monza, Lombardy 20900

3 studies enrolling now · 13 studies all time

What they study most

Advanced Breast Cancer, Alzheimer's Disease, Branch Retinal Vein Occlusion, Breast Cancer, Carcinoma, Carcinoma, Non-Small-Cell Lung, Central Retinal Vein Occlusion, Crohn's Disease, Diabetic Macular Edema, HER2 Amplification, HER2 Gene Mutation, HER2 Mutant Non-small Cell Lung Cancer

Studies at this site

• A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant — Recruiting now
• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease — Recruiting now
• A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9) — Recruiting now
• A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD) — Recruiting now
• A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause — Completed
• A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products — Running, not enrolling
• TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) — Running, not enrolling
• Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer — Running, not enrolling
• A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer — Running, not enrolling
• TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) — Running, not enrolling
• Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer — Running, not enrolling
• ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer — Running, not enrolling
• Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer — Completed